News - Precision BioSciences
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual …
Precision BioSciences, Inc. (DTIL) Latest Stock News & Headlines ...
Get the latest Precision BioSciences, Inc. (DTIL) stock news and headlines to help you in your trading and investing decisions.
Press Releases - Precision BioSciences
Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency
Precision BioSciences Receives $13 Million in Proceeds from …
Sep 3, 2024 · In exchange, Precision received upfront economics valued at $21 million (all figures in USD) consisting of $8 million in cash and a $13 million convertible note. The convertible …
Precision BioSciences, Inc. (DTIL) - Yahoo Finance
Find the latest Precision BioSciences, Inc. (DTIL) stock quote, history, news and other vital information to help you with your stock trading and investing.
Precision BioSciences Announces $40.0 Million Offering of …
Mar 1, 2024 · Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that …
Precision BioSciences Receives First Approval of Clinical Trial ...
DURHAM, N.C., October 24, 2024 -- (BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform …
Precision BioSciences (DTIL) Stock Price, News & Analysis
5 days ago · Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the …
Home - Precision BioSciences
Mar 6, 2012 · At Precision BioSciences we are using our novel ARCUS genome editing technology to develop a new class of medicines designed to overcome and potentially cure, …
Precision BioSciences shares soar on promising gene editing trial ...
Jan 10, 2025 · Investing.com -- Shares of Precision BioSciences, Inc. (NASDAQ: DTIL) soared 60% following the announcement of a complete clinical response in the first infant dosed in a …
- Some results have been removed